Literature DB >> 6282758

Virus-infected colostral cell cytokine stimulation of human leukocyte natural killer cytotoxicity.

S Kohl, L K Pickering, L S Loo.   

Abstract

Natural killer cytotoxicity is an important antiviral defense mechanism. Human peripheral blood mononuclear cells cultured with herpes simplex virus (HSV)-infected cells produced a cytokine. This substance stimulated adult natural killer cytotoxicity from 53.0 +/- 10.5% to 79.8% (P less than 0.01) against HSV-infected target cells. These data resulted in a calculated cytokine-dependent cellular cytotoxicity (CDCC) value of 65.8%. Cytokine production was not stimulated by uninfected cells and was independent of the presence or absence of antibodies to HSV in sera of donors and mononuclear cells. Cells from human colostrum also produced an HSV-stimulated cytokine which mediated CDCC by using both adult (19.8 +/- 3.9%) and neonatal (18.6 +/- 3.4%) mononuclear effectors cells. Colostral cell cytokine production was also independent of donor HSV serology. Not all colostral cultures produced the cytokine, and in general colostrum-stimulated CDCC was lower than peripheral blood leukocyte-stimulated CDCC. Colostral cell cytokine stimulation of neonatal natural killer cytotoxicity may account in part for the increased nonspecific resistance of breast-fed infants to viral infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282758      PMCID: PMC351285          DOI: 10.1128/iai.36.2.691-695.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Protection against experimental necrotizing enterocolitis by maternal milk. I. Role of milk leukocytes.

Authors:  J Pitt; B Barlow; W C Heird
Journal:  Pediatr Res       Date:  1977-08       Impact factor: 3.756

2.  Interferon production by lymphocytes in human milk.

Authors:  G Emödi; M Just
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

3.  Morbidity in breast-fed and artificially fed infants.

Authors:  A S Cunningham
Journal:  J Pediatr       Date:  1977-05       Impact factor: 4.406

4.  Relation of breast versus bottle feeding to hospitalization for gastroenteritis in a middle-class U.S. population.

Authors:  S A Larsen; D R Homer
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

5.  The breastmilk macrophage: a potential vehicle for immunoglobulin transport.

Authors:  W B Pittard; S H Polmar; A A Fanaroff
Journal:  J Reticuloendothel Soc       Date:  1977-12

6.  Breast-feeding protects against respiratory syncytial virus infections.

Authors:  M A Downham; R Scott; D G Sims; J K Webb; P S Gardner
Journal:  Br Med J       Date:  1976-07-31

7.  Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells.

Authors:  S Kohl; S E Starr; J M oleske; S L Shore; R B Ashman; A J Nahmias
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

8.  Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells.

Authors:  J M Oleske; R B Ashman; S Kohl; S L Shore; S E Starr; P Wood; A J Nahmias
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

9.  Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus.

Authors:  S Haahr; L Rasmussen; T C Merigan
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

10.  Use of Semliki forest virus to identify lipid-mediated antiviral activity and anti-alphavirus immunoglobulin A in human milk.

Authors:  J K Welsh; I J Skurrie; J T May
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

View more
  1 in total

1.  Colostral antibody-mediated and cell-mediated immunity contributes to innate and antigen-specific immunity in piglets.

Authors:  Meggan Bandrick; Claudia Ariza-Nieto; Samuel K Baidoo; Thomas W Molitor
Journal:  Dev Comp Immunol       Date:  2013-11-16       Impact factor: 3.636

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.